Skip to content

    HIV & AIDS Health Center

    Font Size
    A
    A
    A

    New 1-a-Day HIV Treatment Approved

    'Quad' Drug Stribild Is 3rd Once-Daily HIV Pill
    By
    WebMD Health News
    Reviewed by Louise Chang, MD

    Aug. 28, 2012 -- The FDA has approved Stribild, the much anticipated once-daily "quad" HIV pill from Gilead Sciences.

    The drug combines same two HIV drugs in Truvada, plus elvitegravir, a new HIV drug that attacks HIV in a different way. The fourth component, also new, boosts elvitegravir.

    It's the third all-in-one, once-a-day HIV pill. The others are Atripla from Gilead and Bristol Myers, approved in 2006, and Complera from Gilead and Janssen, approved in 2011.

    "Over the past decade, co-formulated HIV medicines have simplified therapy for many patients and have become standard of care," Paul Sax, MD, of Brigham and Women's Hospital, says in a Gilead news release.

    Stribild is intended for people who have never taken HIV drugs. It should be taken with food.

    Stribild carries a "black box" safety warning. In rare cases, the drug causes a buildup of lactic acid in the blood. It can also cause severe liver problems. Both of these side effects can be deadly.

    More common side effects include nausea and diarrhea.

    Today on WebMD

    misconception
    How much do you know?
    contemplative man
    What to do now.
     
    research
    Should you be tested?
    HIV under microscope
    What does it mean?
     
    HIV AIDS Screening
    Slideshow
    man opening condom wrapper
    Quiz
     
    HIV AIDS Treatment
    Feature
    Discrimination Stigma
    Feature
     
    Treatment Side Effects
    Feature
    grilled chicken and vegetables
    Article
     
    obese man standing on scale
    Article
    cold sore
    Article